The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis
Aims. Recent randomised controlled trials (RCTs) have shown a significant prognostic benefit of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the cardiovascular (CV) profile of patients with diabetes. This systematic review and meta-analysis aim to provide a concise evaluation of all the avai...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Cardiology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2021/9927533 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561547577131008 |
|---|---|
| author | Vasiliki Tsampasian Ranu Baral Rahul Chattopadhyay Maciej Debski Shruti S Joshi Johannes Reinhold Marc R Dweck Pankaj Garg Vassilios S Vassiliou |
| author_facet | Vasiliki Tsampasian Ranu Baral Rahul Chattopadhyay Maciej Debski Shruti S Joshi Johannes Reinhold Marc R Dweck Pankaj Garg Vassilios S Vassiliou |
| author_sort | Vasiliki Tsampasian |
| collection | DOAJ |
| description | Aims. Recent randomised controlled trials (RCTs) have shown a significant prognostic benefit of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the cardiovascular (CV) profile of patients with diabetes. This systematic review and meta-analysis aim to provide a concise evaluation of all the available evidence for the use of these agents in patients with heart failure (HF) regardless of their baseline diabetes status. Methods and Results. PubMed, Web of Science, and Cochrane library databases were systematically searched from inception until November 20th 2020. Eight studies consisting of 13,275 patients were included in the meta-analysis. For the total population, SGLT2 inhibitors reduced the risk of all-cause mortality (HR: 0.83; 95% CI: 0.75–0.91; I2 0%), hospitalisation for HF (HR: 0.68; 95% CI: 0.61–0.75; I2: 0%), CV death (HR: 0.82; 95% CI: 0.74–0.92; I2: 0%), and hospitalisation for HF or CV death (HR: 0.72; 95% CI: 0.66–0.78; I2: 0%). Subgroup analyses of the total population according to the diabetes status showed that SGLT2 inhibitors significantly reduced the risk of hospitalisation for HF (HR: 0.68; 95% CI: 0.61, 0.75; I2: 0%), as well as the risk of hospitalisation for HF or CV death (HR: 0.72; 95% CI: 0.66, 078; I2: 0%) and CV death (HR: 0.82; 95% CI: 0.74, 0.91; I2: 0%). Conclusions. The results of this meta-analysis confirm the growing evidence in the literature of the favourable profile of SGLT2 inhibitors in cardiovascular outcomes and mortality in patients with heart failure regardless of the baseline diabetes status. This systematic review has been registered with PROSPERO (CRD42021224777). |
| format | Article |
| id | doaj-art-18662660bd414ec981f3801a3c363db5 |
| institution | Kabale University |
| issn | 2090-8016 2090-0597 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiology Research and Practice |
| spelling | doaj-art-18662660bd414ec981f3801a3c363db52025-02-03T01:24:41ZengWileyCardiology Research and Practice2090-80162090-05972021-01-01202110.1155/2021/99275339927533The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-AnalysisVasiliki Tsampasian0Ranu Baral1Rahul Chattopadhyay2Maciej Debski3Shruti S Joshi4Johannes Reinhold5Marc R Dweck6Pankaj Garg7Vassilios S Vassiliou8Department of Cardiology, Norfolk and Norwich University Hospitals, Norwich, UKDepartment of Cardiology, Norfolk and Norwich University Hospitals, Norwich, UKDepartment of Cardiology, Cambridge University Hospitals, Cambridge, UKDepartment of Cardiology, Norfolk and Norwich University Hospitals, Norwich, UKUniversity of Edinburgh/British Heart Foundation Centre for Cardiovascular Science, Edinburgh, UKDepartment of Cardiology, Norfolk and Norwich University Hospitals, Norwich, UKUniversity of Edinburgh/British Heart Foundation Centre for Cardiovascular Science, Edinburgh, UKDepartment of Cardiology, Norfolk and Norwich University Hospitals, Norwich, UKDepartment of Cardiology, Norfolk and Norwich University Hospitals, Norwich, UKAims. Recent randomised controlled trials (RCTs) have shown a significant prognostic benefit of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the cardiovascular (CV) profile of patients with diabetes. This systematic review and meta-analysis aim to provide a concise evaluation of all the available evidence for the use of these agents in patients with heart failure (HF) regardless of their baseline diabetes status. Methods and Results. PubMed, Web of Science, and Cochrane library databases were systematically searched from inception until November 20th 2020. Eight studies consisting of 13,275 patients were included in the meta-analysis. For the total population, SGLT2 inhibitors reduced the risk of all-cause mortality (HR: 0.83; 95% CI: 0.75–0.91; I2 0%), hospitalisation for HF (HR: 0.68; 95% CI: 0.61–0.75; I2: 0%), CV death (HR: 0.82; 95% CI: 0.74–0.92; I2: 0%), and hospitalisation for HF or CV death (HR: 0.72; 95% CI: 0.66–0.78; I2: 0%). Subgroup analyses of the total population according to the diabetes status showed that SGLT2 inhibitors significantly reduced the risk of hospitalisation for HF (HR: 0.68; 95% CI: 0.61, 0.75; I2: 0%), as well as the risk of hospitalisation for HF or CV death (HR: 0.72; 95% CI: 0.66, 078; I2: 0%) and CV death (HR: 0.82; 95% CI: 0.74, 0.91; I2: 0%). Conclusions. The results of this meta-analysis confirm the growing evidence in the literature of the favourable profile of SGLT2 inhibitors in cardiovascular outcomes and mortality in patients with heart failure regardless of the baseline diabetes status. This systematic review has been registered with PROSPERO (CRD42021224777).http://dx.doi.org/10.1155/2021/9927533 |
| spellingShingle | Vasiliki Tsampasian Ranu Baral Rahul Chattopadhyay Maciej Debski Shruti S Joshi Johannes Reinhold Marc R Dweck Pankaj Garg Vassilios S Vassiliou The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis Cardiology Research and Practice |
| title | The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis |
| title_full | The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis |
| title_fullStr | The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis |
| title_short | The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis |
| title_sort | role of sglt2 inhibitors in heart failure a systematic review and meta analysis |
| url | http://dx.doi.org/10.1155/2021/9927533 |
| work_keys_str_mv | AT vasilikitsampasian theroleofsglt2inhibitorsinheartfailureasystematicreviewandmetaanalysis AT ranubaral theroleofsglt2inhibitorsinheartfailureasystematicreviewandmetaanalysis AT rahulchattopadhyay theroleofsglt2inhibitorsinheartfailureasystematicreviewandmetaanalysis AT maciejdebski theroleofsglt2inhibitorsinheartfailureasystematicreviewandmetaanalysis AT shrutisjoshi theroleofsglt2inhibitorsinheartfailureasystematicreviewandmetaanalysis AT johannesreinhold theroleofsglt2inhibitorsinheartfailureasystematicreviewandmetaanalysis AT marcrdweck theroleofsglt2inhibitorsinheartfailureasystematicreviewandmetaanalysis AT pankajgarg theroleofsglt2inhibitorsinheartfailureasystematicreviewandmetaanalysis AT vassiliossvassiliou theroleofsglt2inhibitorsinheartfailureasystematicreviewandmetaanalysis AT vasilikitsampasian roleofsglt2inhibitorsinheartfailureasystematicreviewandmetaanalysis AT ranubaral roleofsglt2inhibitorsinheartfailureasystematicreviewandmetaanalysis AT rahulchattopadhyay roleofsglt2inhibitorsinheartfailureasystematicreviewandmetaanalysis AT maciejdebski roleofsglt2inhibitorsinheartfailureasystematicreviewandmetaanalysis AT shrutisjoshi roleofsglt2inhibitorsinheartfailureasystematicreviewandmetaanalysis AT johannesreinhold roleofsglt2inhibitorsinheartfailureasystematicreviewandmetaanalysis AT marcrdweck roleofsglt2inhibitorsinheartfailureasystematicreviewandmetaanalysis AT pankajgarg roleofsglt2inhibitorsinheartfailureasystematicreviewandmetaanalysis AT vassiliossvassiliou roleofsglt2inhibitorsinheartfailureasystematicreviewandmetaanalysis |